Is IRadimed Corp. overvalued or undervalued?

As of 3 September 2025, the valuation grade for IRadimed Corp. has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 39, an EV to EBITDA of 30.68, and a Price to Book Value of 8.54. In comparison, its peer Artivion, Inc. has a significantly higher P/E ratio of 44.24, while BioLife Solutions, Inc. shows a negative P/E, highlighting IRadimed's relatively favorable valuation position within the industry.
In terms of performance, IRadimed has demonstrated strong returns, with a year-to-date return of 31.59% compared to the S&P 500's 12.22%, and a remarkable 5-year return of 224.55% against the S&P 500's 96.61%. This performance reinforces the notion that the stock is undervalued relative to its growth potential and industry peers.